一名接受奥曲肽和西罗莫司治疗的胰岛细胞瘤患者发生致命性乙型肝炎再激活。
Fatal hepatitis B reactivation in a patient with islet cell tumor on octreotide and sirolimus.
作者信息
DeFilippis Ersilia M, Ludwig Emmy
机构信息
Department of Medicine, Memorial Sloan Kettering Cancer Center, Gastroenterology and Nutrition Service, New York, NY 10065, USA.
出版信息
J Gastrointest Oncol. 2015 Oct;6(5):E66-9. doi: 10.3978/j.issn.2078-6891.2015.042.
Abstract
Reactivation of hepatitis B viral infection (HBVr) is a known risk in cancer patients with a history of chronic hepatitis B infection receiving cytotoxic or immunosuppressive therapies. Patients with hematologic malignancies or those who have received stem cell transplantation seem to be most at risk but reactivation has been reported with various malignancies. Reactivation can present as asymptomatic liver function test abnormalities (LFTs), with symptoms of abdominal pain, encephalopathy, or as fulminant hepatitis and liver failure. Here we report the first case of a patient with islet cell tumor on octreotide and sirolimus who developed hepatitis B reactivation with fulminant liver failure and death.
摘要
乙型肝炎病毒感染再激活（HBVr）是有慢性乙型肝炎感染史的癌症患者接受细胞毒性或免疫抑制治疗时已知的风险。血液系统恶性肿瘤患者或接受过干细胞移植的患者似乎风险最高，但各种恶性肿瘤患者均有再激活的报道。再激活可表现为无症状的肝功能检查异常（LFTs）、伴有腹痛、脑病症状，或表现为暴发性肝炎和肝衰竭。在此，我们报告首例接受奥曲肽和西罗莫司治疗的胰岛细胞瘤患者发生乙型肝炎再激活并导致暴发性肝衰竭和死亡的病例。
相似文献
1
Fatal hepatitis B reactivation in a patient with islet cell tumor on octreotide and sirolimus.
J Gastrointest Oncol. 2015 Oct;6(5):E66-9. doi: 10.3978/j.issn.2078-6891.2015.042.
2
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
World J Gastroenterol. 2016 Jul 28;22(28):6484-500. doi: 10.3748/wjg.v22.i28.6484.
3
HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review.
Viruses. 2019 Nov 10;11(11):1049. doi: 10.3390/v11111049.
4
Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-Screened.
Hepat Mon. 2016 Mar 26;16(4):e35810. doi: 10.5812/hepatmon.35810. eCollection 2016 Apr.
5
Hepatitis B Virus Reactivation in the Setting of Immunosuppressive Drug Therapy.
Gastroenterol Hepatol (N Y). 2019 Nov;15(11):585-592.
6
Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy.
Clin Infect Dis. 2016 Jun 1;62 Suppl 4(Suppl 4):S306-13. doi: 10.1093/cid/ciw043.
7
Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure.
World J Hepatol. 2015 May 8;7(7):954-67. doi: 10.4254/wjh.v7.i7.954.
8
Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature.
Breast Cancer Res Treat. 2013 Sep;141(2):167-72. doi: 10.1007/s10549-013-2681-0. Epub 2013 Sep 4.
9
Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report.
J Med Case Rep. 2015 Jul 28;9:164. doi: 10.1186/s13256-015-0630-8.
10
Hepatitis B Reactivation and Liver Failure Because of COVID-19 Infection.
ACG Case Rep J. 2024 Jun 27;11(7):e01397. doi: 10.14309/crj.0000000000001397. eCollection 2024 Jul.
引用本文的文献
1
Everolimus Related Fulminant Hepatitis in Pancreatic Neuroendocrine Tumor With Liver Metastases: A Case Report and Literature Review.
Front Endocrinol (Lausanne). 2021 Apr 1;12:639967. doi: 10.3389/fendo.2021.639967. eCollection 2021.
2
Successful Sirolimus Treatment of Lymphangioleiomyomatosis in a Hepatitis B Virus Carrier.
Intern Med. 2019 Feb 15;58(4):569-574. doi: 10.2169/internalmedicine.1329-18. Epub 2018 Oct 17.
本文引用的文献
1
The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis.
J Formos Med Assoc. 2015 Feb;114(2):164-73. doi: 10.1016/j.jfma.2012.10.007. Epub 2012 Dec 20.
2
Prospective study of hepatitis B virus reactivation in patients with hematological malignancies.
Ann Hepatol. 2015 Mar-Apr;14(2):168-74.
3
The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system.
PLoS One. 2015 Feb 6;10(2):e0116978. doi: 10.1371/journal.pone.0116978. eCollection 2015.
4
Universal hepatitis B virus screening in patients receiving immunosuppressive therapy: a small step for the oncologists, a major advance for prevention of hepatitis B virus reactivation.
Clin Gastroenterol Hepatol. 2015 May;13(5):976-8. doi: 10.1016/j.cgh.2015.01.013. Epub 2015 Jan 26.
5
Reactivation of hepatitis B virus 40 months after discontinuation of rituximab maintenance treatment and 5 months after cessation of entecavir administration.
Clin Res Hepatol Gastroenterol. 2015 Jun;39(3):e39-40. doi: 10.1016/j.clinre.2014.11.005. Epub 2014 Dec 30.
6
Optimal antiviral prophylaxis against hepatitis B reactivation in patients receiving rituximab-based chemotherapy for lymphoma.
JAMA. 2014 Dec 17;312(23):2505-7. doi: 10.1001/jama.2014.16095.
7
Hepatitis B virus screening and potential reactivation in patients undergoing treatment for cancer.
J Natl Compr Canc Netw. 2014 Dec;12(12):1655-7. doi: 10.6004/jnccn.2014.0166.
8
[Fulminant acute hepatitis B after infliximab treatment in Crohn's disease].
Tunis Med. 2014 May;92(5):349-50.
9
American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.
Gastroenterology. 2015 Jan;148(1):221-244.e3. doi: 10.1053/j.gastro.2014.10.038. Epub 2014 Oct 31.
10
Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
J Clin Oncol. 2014 Nov 20;32(33):3736-43. doi: 10.1200/JCO.2014.56.7081. Epub 2014 Oct 6.
Zotero 插件